ELOX: Q1 2026 net loss rose to $3.8M, cash insufficient for 12 months, all debt eliminated via equity

About this update from Eloxx Pharmaceuticals, Inc.

Net loss widened to $3.8M in Q1 2026 as R&D and G&A expenses surged, with cash reserves of $6.4M deemed insufficient for the next year. The company eliminated all debt via equity conversions but faces substantial going concern risks and is seeking additional capital. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Eloxx Pharmaceuticals, Inc.